[HTML][HTML] Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years
T Cufer, T Ovcaricek, MER O'Brien - European journal of cancer, 2013 - Elsevier
The standard palliative treatment for advanced stage NSCLC remains a platinum doublet
but by tailoring chemotherapy according to tumour histology the results can be improved …
but by tailoring chemotherapy according to tumour histology the results can be improved …
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
A Tartarone, C Lazzari, R Lerose, V Conteduca… - Lung cancer, 2013 - Elsevier
The discovery of several molecular alterations that underlie non-small cell lung cancer
(NSCLC) pathogenesis has led to the development of targeted therapies. In particular …
(NSCLC) pathogenesis has led to the development of targeted therapies. In particular …
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well
JL Kuiper, EF Smit - Lung cancer, 2013 - Elsevier
A considerable number of patients with epidermal growth factor receptor (EGFR)-mutated
non-small-cell lung cancer (NSCLC) develop leptomeningeal metastases. Leptomeningeal …
non-small-cell lung cancer (NSCLC) develop leptomeningeal metastases. Leptomeningeal …
[HTML][HTML] Irreversible EGFR-TKIs: dreaming perfection
L Landi, F Cappuzzo - Translational lung cancer research, 2013 - ncbi.nlm.nih.gov
In the last few years, the treatment of Non-Small-Cell Lung Cancer (NSCLC) has
dramatically changed. Presence of activating mutations in the Epidermal Growth Factor …
dramatically changed. Presence of activating mutations in the Epidermal Growth Factor …
Erlotinib in the first-line treatment of non-small-cell lung cancer
M D'Arcangelo, F Cappuzzo - Expert review of anticancer therapy, 2013 - Taylor & Francis
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …
MET overexpression and gene amplification in NSCLC: a clinical perspective
L Landi, G Minuti, A D'Incecco, J Salvini… - Lung Cancer: Targets …, 2013 - Taylor & Francis
The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET) receptor and
its ligand, hepatocyte growth factor, also known as scatter factor, have recently been …
its ligand, hepatocyte growth factor, also known as scatter factor, have recently been …
[HTML][HTML] Strategies for improving outcomes in NSCLC: a look to the future
Advances in the management of non-small cell lung cancer (NSCLC) over the past 30 years
have led to small increases in 5-year survival rates across Europe, though further …
have led to small increases in 5-year survival rates across Europe, though further …
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
S Zimmermann, S Peters - Cancer and Metastasis Reviews, 2015 - Springer
The development of novel effective immunotherapeutic agents and early clinical data hinting
at significant activity in non-small cell lung cancer (NSCLC) has introduced yet another …
at significant activity in non-small cell lung cancer (NSCLC) has introduced yet another …
[HTML][HTML] 培美曲塞和吉非替尼不同时序应用对人肺腺癌细胞的作用和机制
边劲， 王琳， 寻琛， 黄伟， 秦叔逵 - 肿瘤防治研究, 2014 - zlfzyj.com
目的探讨培美曲塞与吉非替尼不同时序应用对肺腺癌细胞A549 和PC-9 生长及凋亡的影响,
并阐述其可能机制. 方法MTT 法检测各组细胞的增殖抑制情况, 流式细胞仪检测各组细胞凋亡及 …
并阐述其可能机制. 方法MTT 法检测各组细胞的增殖抑制情况, 流式细胞仪检测各组细胞凋亡及 …
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
HF Kao, CC Lin, JCH Yang - Future Oncology, 2013 - Taylor & Francis
Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell
lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and …
lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and …